Urolithin A and Cardiovascular Aging: What the Research Shows (and What It Doesn't)
Key takeaways
- Urolithin A is a mitophagy compound. It is a postbiotic metabolite most studied for supporting the cellular recycling of aging mitochondria and overall mitochondrial quality.
- The cardiovascular evidence is largely preclinical. Much of what suggests a link between Urolithin A and cardiovascular tissue comes from cell and animal research on mitochondrial biology—not from human outcomes.
- Human trials have NOT measured cardiovascular clinical endpoints. Randomized human studies to date looked at skeletal muscle, mitochondrial biomarkers, and immune markers—not the heart or blood vessels as clinical outcomes.
- Mitochondria matter across the body. The rationale for interest is mechanistic: heart and vascular cells are energy-hungry, so mitochondrial quality is a broadly relevant research theme—this is a hypothesis, not a proven human benefit.
- Talk to a healthcare provider. If you have questions about your heart, a cardiologist—not a supplement—is the right starting point.
What Urolithin A is and how it works
Urolithin A is a compound your gut microbiome can produce when it metabolizes ellagitannins and ellagic acid—polyphenols found in foods like pomegranates, walnuts, and certain berries. Not everyone's microbiome makes meaningful amounts of it, which is part of why it is studied as a direct supplement rather than relying on diet alone. You can read a broader overview in our guide to Urolithin A benefits.
The mechanism researchers focus on is mitophagy—the cellular "quality-control" process that identifies worn-out or dysfunctional mitochondria and recycles them so healthier ones can take their place. Mitochondria are the structures that produce most of your cells' usable energy, and their efficiency tends to decline with age. For a deeper explanation, see our article on what mitophagy is and how it relates to mitochondrial dysfunction and aging.
The foundational human pharmacokinetic and safety work published in Nature Metabolism (2019) showed that oral Urolithin A is bioavailable in humans and can influence mitochondrial and cellular-energy gene signatures. That is a structure/function observation about cellular biology—not a cardiovascular claim.
Why researchers connect mitochondria to cardiovascular aging
Here is the mechanistic rationale, stated plainly and labeled for what it is. The heart and the cells lining your blood vessels are among the most energy-demanding tissues in the body, so they contain large numbers of mitochondria. Because mitochondrial quality is a recurring theme in the biology of aging, scientists naturally ask whether interventions that support mitophagy could be relevant to tissues that rely heavily on mitochondria—including cardiovascular tissue.
This is where honesty matters most. The work exploring Urolithin A specifically in cardiovascular or vascular tissue is preclinical—conducted in cell cultures and animal models examining mitochondrial function and mitophagy. Preclinical research is where hypotheses are generated, not where human benefits are established. Animal and cell findings frequently do not translate to people, and a mechanism observed in a dish or a mouse does not mean a supplement "supports the heart" in humans. Treat this section as scientific context and rationale, not as evidence of a cardiovascular effect in people.
What human Urolithin A trials have—and have not—measured
This is the most important part of the article. Randomized, placebo-controlled human trials of Urolithin A have generally focused on skeletal muscle, mitochondrial biomarkers, and markers of cellular and immune health—not on cardiovascular clinical endpoints.
The randomized trial published in Cell Reports Medicine (2022) examined middle-aged adults and reported changes in mitochondrial and cellular-energy biomarkers along with certain measures of muscle performance. More recent work in Nature Aging (2025) continued to explore mitochondrial and muscle-related outcomes. Related brand research also looks at exercise physiology measures such as endurance and VO2 max. What none of these human trials did was demonstrate a benefit for heart disease, blood pressure, cholesterol, or any other cardiovascular clinical outcome. Those endpoints were not the goal, and the results should not be read as if they were.
So the honest summary is this: in humans, Urolithin A has been studied as a mitochondrial and muscle-support compound. Any leap from "supports mitochondrial quality" to "supports the heart" is not backed by human cardiovascular trials at this time.
| What has been shown in humans | What is preclinical or hypothesized only |
|---|---|
| Oral Urolithin A is bioavailable and can influence mitochondrial and cellular-energy gene signatures | Effects on cardiac or vascular tissue (studied in cells and animals, not people) |
| Changes in mitochondrial biomarkers in middle-aged and older adults | Any translation of mitophagy mechanisms into human heart outcomes |
| Measures related to skeletal muscle performance and endurance physiology | Benefits for blood pressure, cholesterol, or cardiovascular disease risk |
| Certain immune and cellular-health markers | A "heart-supporting" effect in humans of any kind |
How to think about Urolithin A responsibly
If you are between 45 and 70 and researching whether Urolithin A has cardiovascular relevance, the responsible framing is: it is a compound studied for mitochondrial quality and mitophagy, with meaningful human data on muscle and mitochondrial biomarkers and only preclinical exploration of cardiovascular tissue. It is not a treatment, and it is not a substitute for anything your doctor may recommend.
Cardiovascular health is a serious, individual matter. If you have concerns about your heart—or a family history, symptoms, or existing conditions—the right step is a conversation with a healthcare provider or cardiologist, who can consider your full history, medications, and lab work. Supplements can also interact with medications, so a provider should review anything new you are considering. This article is educational and does not diagnose, treat, or prevent any condition.
For readers who simply want to support general mitochondrial and cellular-energy biology as part of a broader healthy-aging routine, SOMA Urolithin A gummies deliver a studied dose in a convenient form—framed honestly around mitochondrial support, not cardiovascular claims.
Frequently asked questions
Does Urolithin A improve heart health?
No—that has not been demonstrated. Human randomized trials of Urolithin A measured muscle, mitochondrial biomarkers, and immune markers, not cardiovascular clinical outcomes. Research touching cardiovascular tissue is preclinical (cells and animals). If heart health is your concern, talk to a healthcare provider or cardiologist.
Is there any human evidence linking Urolithin A to the cardiovascular system?
Not in the sense of proven cardiovascular benefits. Human studies have focused on mitochondrial and muscle-related outcomes. The cardiovascular-tissue work is preclinical and mechanistic, meaning it explores biology in cells and animals rather than establishing effects in people.
Why do people associate Urolithin A with cardiovascular aging at all?
Because the heart and blood vessels are energy-intensive tissues rich in mitochondria, and Urolithin A is studied for mitochondrial quality and mitophagy. That connection is a mechanistic rationale for research interest—not evidence that the supplement supports the heart in humans.
What have human Urolithin A trials actually shown?
They have shown that oral Urolithin A is bioavailable and can influence mitochondrial and cellular-energy biomarkers, with additional measures related to skeletal muscle and endurance physiology. These are structure/function observations about cellular energy, not cardiovascular outcomes.
Should I take Urolithin A for my heart?
No supplement should be used to address a cardiovascular concern on your own. Urolithin A is studied for mitochondrial support, not heart conditions. Bring any cardiovascular question—and any supplement you are considering—to a qualified healthcare provider who knows your history.
Support your cellular health, every day
SOMA delivers a high-potency 1,000 mg dose of Urolithin A in one simple daily gummy — no guesswork, no converter-status lottery.
Shop SOMA Urolithin A Gummies →These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.